Corneal Ulcer Pipeline Analysis Demonstrates Novel Therapies at the Horizon Expected to Transform the Treatment Paradigm | DelveInsight
Los Angeles, June 10, 2021 (GLOBE NEWSWIRE) — Corneal Ulcer Pipeline Analysis Demonstrates Novel Therapies at the Horizon Expected to Transform the Treatment Paradigm | DelveInsight
The majority of the drugs for Corneal Ulcer are in the early stages of development and in coming years the market is expected to grow.
DelveInsight’s ‘Corneal Ulcer Pipeline Insights’ report provides the current treatment landscape and rich analysis of pipeline therapies in different stages of development from pre-clinical till late-stage, along with dormant, inactive, and abandoned therapeutic agents.
Some of the key pointers from the Corneal Ulcer Pipeline report:
- Corneal Ulcer Pipeline report offers a rich analysis of 6+ key pharma companies and 6+ key therapies.
- Corneal Ulcer pipeline comprises therapies in different stages of trials such as SREC 0559, OC01, CSB-001, BD-111, NRO-1, Rose bengal sodium, among others.
- Key pharma companies working to make the Corneal Ulcer pipeline robust include Recordati/Mime Tech, Oyster Point Pharma, Claris Biotherapeutics, Shanghai BDgene, Neuroptika, Provectus Biopharmaceuticals, among others.
- FDA granted Orphan Drug Designation to Recordati Rare Diseases investigational product REC 0559 for the treatment of neurotrophic keratitis.
Discover more about the pharma company and therapy expected to grab maximum share by requesting sample report @ Corneal Ulcer Emerging Therapies and Forecast
Corneal Ulcer: Overview
Corneal Ulcer, also known as Keratitis, is characterized by damage or loss of the epithelial layer associated with infiltration of the underlying corneal stroma.
Whilst the treatment of refractory corneal ulcers is challenging, it is essential that they are resolved as they can quickly endanger the anatomical integrity of the ocular surface or the transparency of the cornea.
Discover more about disease outlook, available therapies, and emerging drugs, visit Corneal Ulcer Pipeline Analysis
Corneal Ulcer Drug Pipeline Assessment
|REC 0559||Recordati/Mime Tech||Phase II||Apoptosis inhibitors; Autophagy inhibitors; Nerve growth factor receptor agonists||Eye drop solution|
|OC01||Oyster Point Pharma||Preclinical||Alpha4 beta2 nicotinic receptor agonists||NA|
|CSB-001||Claris Biotherapeutics||Phase I/II||NA||Ophthalmic Solution|
|BD-111||Shanghai BDgene||Phase I/II||Undefined mechanism||corneal injection|
|NRO-1||Neuroptika||Phase I||Glial cell line-derived neurotrophic factor agonists||Topical|
|Rose bengal sodium||Provectus Biopharmaceuticals||Preclinical||Cell death stimulants; Cell membrane modulators; Dendritic cell stimulants; Immunostimulants; Interferon modulators; Interleukin 17 modulators; Interleukin-22 modulators||Topical|
Request for Sample to know more @ Corneal Ulcer Pipeline Analysis, Key Companies, and Futuristic Trends
Corneal Ulcer Therapeutics Assessment
The Corneal Ulcer Pipeline report lays down a comprehensive coverage of the active pipeline candidates segmented by Stage, Product Type, Route of Administration (RoA), Molecule Type, Target, and Mechanism of Action (MoA).
By Product Type
- Phase I
- Phase II
- Phase III
By Molecule Type
- Monoclonal Antibody
- Small molecule
- Gene therapy
- Product Type
By Route of Administration
- Molecule Type
By Mechanism of Action
- Nerve growth factor receptor agonists
- Glial cell line-derived neurotrophic factor agonists
- Alpha4 beta2 nicotinic receptor agonists
- Autophagy inhibitors
- Cell membrane modulators
- Autophagy inhibitors
- Nerve growth factor receptor
- Glial cell line-derived neurotrophic factor
- Alpha4 beta2 nicotinic receptor
Connect with our Business Executive for Asset Prioritization Services and Consulting Solutions
Scope of the Corneal Ulcer Pipeline Report
Key Players: Recordati/Mime Tech, Oyster Point Pharma, Claris Biotherapeutics, Shanghai BDgene, Neuroptika, Provectus Biopharmaceuticals, OcuNexus Therapeutics, Santen S.A.S., FirstString Research, Regeneratetx, Stuart Therapeutics, EyeGate Pharmaceuticals, Trefoil Therapeutics, AmebaGone Inc., Dobecure, Editas medicine, and others.
Key Corneal Ulcer Pipeline Therapies: REC 0559, OC01, CSB-001, BD-111, NRO-1, Rose bengal sodium, and others.
Reach out @ Corneal Ulcer Pipeline: Novel therapies and Emerging technologies
Table of Contents
|2||Corneal Ulcer Disease Overview|
|3||Corneal Ulcer Pipeline Therapeutics|
|5||Corneal Ulcer – DelveInsight’s Analytical Perspective|
|6||In-depth Commercial Assessment|
|7||Corneal Ulcer Collaboration Deals|
|8||Corneal Ulcer Therapeutic Products in Clinical Stage|
|9||Corneal Ulcer Therapeutic Products in Non-clinical Stage|
|10||Corneal Ulcer Therapeutics Pipeline Analysis|
|11||Inactive Corneal Ulcer Pipeline Products|
|12||Corneal Ulcer Key Companies|
|13||Corneal Ulcer Key Products|
|14||Corneal Ulcer- Unmet Needs|
|15||Corneal Ulcer Market Drivers and Barriers|
|16||Corneal Ulcer- Future Perspectives and Conclusion|
|17||Corneal Ulcer Analyst Views|
Learn more about the report offerings @ Corneal Ulcer Emerging Therapies, Treatments and Ongoing Clinical Trials
Corneal Ulcer Market
DelveInsight’s “Corneal Ulcer – Market Insights, Epidemiology, and Market Forecast-2030” report.
Peptic Ulcer Hemorrhage Market
DelveInsight’s “Peptic Ulcer Hemorrhage – Market Insights, Epidemiology, and Market Forecast-2030” report.
Varicose Ulcer Market
DelveInsight’s ” Varicose Ulcer – Market Insights, Epidemiology, and Market Forecast-2030″ report.
Venous Leg Ulcer Market
DelveInsight’s “Venous Leg Ulcer – Market Insights, Epidemiology, and Market Forecast-2030” report.
Global Burden of Cytomegalovirus Seroprevalence
Analysis of therapies and key companies such as Merck, Helocyte, Shire, Atara Biotherapeutics, ViraCyte, and others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
For more insights, visit Pharma, Healthcare, and Biotech News
We are now on Telegram. Click here to join our channel (@TechiUpdate) and stay updated with the latest Technology headlines.
For all the latest Health News Click Here